Open AccessA cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospital
Author(s) -
Uma A Bhosale,
Nilofar Quraishi,
Radha Yegnanarayan,
Dileep Devasthale
Publication year - 2014
Publication title -
nigerian medical journal/nigerian medical journal
Language(s) - English
Resource type - Journals
eISSN - 2229-774X
pISSN - 0300-1652
DOI - 10.4103/0300-1652.140386
Subject(s) - medicine , rofecoxib , etoricoxib , celecoxib , valdecoxib , proportional hazards model , body mass index , cyclooxygenase , prospective cohort study , cohort , meloxicam , adverse effect , biochemistry , chemistry , enzyme
Cyclooxygenase-2 inhibitors (COX-2-Is) have recently been concerned in the occurrence of adverse cardiovascular (CV) events. Rofecoxib and valdecoxib has been withdrawn from the market, but celecoxib, etoricoxib and parecoxib continues to be used. Other nonsteroidal anti-inflammatory drugs (NSAIDs) may also increase the risk of CV events. However, clinical trial databases for COX-2-Is had created lots of controversies regarding cardiovascular safety of selective and nonselective cyclooxygenase inhibitors (COX-Is). This study was, conducted to assess and compare the CV risk of COX-Is in arthritic patients over a period of time.